Sai Life Sciences Limited Earnings Summary — Q1 FY2027
Sai Life Sciences Reports 11.7% YoY Revenue Growth in Q1 FY2027 Amidst Sequential Softness
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue declined 7.9% sequentially in Q1 FY2027.
- Revenue of ₹554 Cr is 11.7% higher year-on-year.
- Revenue has compounded at 10.9% annualised over the last 10 quarters.
- Net profit of ₹73 Cr is 21.2% above the same quarter last year.
- Profit growth is outpacing revenue growth, pointing to positive operating leverage.
- Net profit has compounded at 14.3% annualised across the period.
- Operating margin stands at 26.7% in Q1 FY2027.
- Operating margin expanded by 234 bps year-on-year.
- Over the last two years operating margin has expanded by 1736 bps.
- PBT margin is 17.7%.
- Expense growth of 8.2% remained below revenue growth of 11.7%.
- Operating profit of ₹148 Cr is 22.4% higher year-on-year.
- Operating leverage continues to improve.
- 6 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 69/100 (Healthy) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 554 | 602 | 556 | 537 | 496 | 580 | 440 | 396 | 280 | 439 |
| Expenses | Improving | 406 | 426 | 369 | 392 | 375 | 422 | 320 | 293 | 254 | 315 |
| Operating Profit | Volatile | 148 | 177 | 188 | 146 | 121 | 158 | 120 | 102 | 26 | 125 |
| Operating Margin | Volatile | 26.7% | 29.3% | 33.8% | 27.1% | 24.4% | 27.2% | 27.2% | 25.8% | 9.3% | 28.4% |
| Other Income | Volatile | 4 | 16 | 0 | 15 | 10 | 10 | 9 | 10 | 8 | 3 |
| Interest | Softening | 8 | 8 | 10 | 9 | 12 | 11 | 23 | 21 | 21 | 21 |
| Depreciation | Improving | 46 | 45 | 44 | 40 | 38 | 37 | 34 | 36 | 31 | 31 |
| Profit Before Tax | Volatile | 98 | 139 | 134 | 112 | 81 | 119 | 72 | 55 | -18 | 76 |
| Tax | Volatile | 25 | 35 | 34 | 28 | 20 | 31 | 18 | 14 | -5 | 20 |
| Net Profit | Volatile | 73 | 104 | 100 | 84 | 60 | 88 | 54 | 42 | -13 | 56 |
| Net Margin | Volatile | 13.2% | 17.3% | 18.0% | 15.6% | 12.2% | 15.2% | 12.2% | 10.5% | -4.8% | 12.8% |
Key Takeaways
- Consolidated revenue reached ₹5,542.85 million, marking an 11.7% increase compared to the same quarter last year.
- Net profit grew by 21.2% YoY to ₹732.85 million, although it saw a significant sequential decline from the previous quarter's ₹1,042.36 million.
- Employee benefit expenses rose 12% YoY to ₹1,799.04 million, reflecting continued investment in talent for the CRDMO platform.
- Finance costs significantly decreased to ₹76.36 million from ₹123.64 million in the year-ago quarter, indicating successful deleveraging.
- The company continues to operate as a single-segment entity focused on Contract Research, Development, and Manufacturing Services.
- Diluted EPS improved to ₹3.42 from ₹2.83 in Q1 FY2026, despite a minor increase in the equity base due to ESOP exercises.
Management Guidance
Management maintains a focus on transitioning toward high-margin commercial molecules and improving capacity utilization across its integrated CRDMO platform.
Sentiment Shift
Stable
Year-on-year growth remains healthy across revenue and profitability, though sequential performance was weaker following a strong Q4 FY2026.
Outlook
The outlook remains constructive as the company leverages its recent multi-year investment phase to scale commercial projects and drive margin expansion through operational leverage.
From the Annual Report (Key Quotes)
“The Company operates in a single segment of providing 'Contract Research, Development and Manufacturing Services (CRDMO)'.”
“The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Sai Life Sciences Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.